Our management team is represented by industry professionals with extensive experience in the pharmaceutical industry and a track record of delivering shareholder return.
COO/CFO and Director
Liz joined Enesi Pharma in August 2021 and has over 20 years pharmaceutical industry experience, a strong background in clinical development and a proven track record of driving results focussed operational excellence.
Prior to joining Enesi, Liz was Senior Director and Head of Clinical Operations, Vaccitech (UK), a vaccine company spun out from Oxford University. She worked alongside the senior leadership to set strategy while building high functioning teams and successfully leading all programmes into early stage, clinical studies, during a high value funding round and IPO.
Before Vaccitech, she was Project Director and Director of Patient Engagement at Covance, a leading international contract research organisation, building collaborative networks of patient advocates, and financially managing clinical programmes with high value large pharmaceutical clients.
Liz also led a number of clinical programmes at Vectura (UK), a leading inhaled product development company leveraging proprietary device and formulation technologies, during a period of acquisition and growth, creating and implementing vendor procurement and management processes, and successfully completing first in human clinical studies.
Liz holds a BSc (Hons) in biology with analytical chemistry, and a Master’s Degree in Business Administration from the University of Liverpool (UK).
Dr Keith Howard
Keith joined Enesi in 2020 and brings more than 35 years of experience in vaccine development spent in industry and academia and has led the development of viral vectors and vaccines across multiple formats (recombinant, viral vector, live attenuated virus) at several biotechnology and pharmaceutical companies.
Prior to joining Enesi, Keith was Chief Development Officer at Oxford-based Vaccitech, where he was the head of R&D, process development and manufacturing for its novel viral vector vaccine programmes. Before that, he was Senior Director and Head of Manufacturing Science & Technology for FluMist (live attenuated influenza vaccine) at Medimmune.
Before this, Keith was a Director of Vaccines Analytical Development at Pfizer Biotech, and he also spent ten years at Baxter AG in various positions including that of Director of Vaccines R&D. Further roles included Head of Vector Development at Oxxon Therapeutics and Director of Neuronal Gene Therapy at Cantab Pharmaceuticals.
Keith spent 13 years in academia studying infectious diseases, virology and immunology at University College London and the London School of Hygiene and Tropical Medicine. He received a BSc in Biological Sciences from the University of Leicester and a PhD in Molecular Parasitology from the University of London.